BIOMAT Database Logo BIOMAT Database Logo

Effects of subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. 1993

B Di Paolo, and A Marini, and B Fiederling, and L Di Liberato, and P Santarelli, and S Bucciarelli, and S Stuard, and L Paolantonio, and A Albertazzi
Department of Nephrology and Dialysis, University of Chieti, Italy.

The use of recombinant human erythropoietin (rHuEPO) has revolutionized the treatment of renal anemia, but the dose regimens, the optimal frequency, and the effects on other target organs like the central nervous systems (CNS) are still under discussion. We designed a prospective, ongoing study with 10 stable continuous ambulatory peritoneal dialysis (CAPD) patients (6 males, 4 females; mean age 64.4 +/- 7.8 years), with a pretreatment hemoglobin (Hb) < 7.0 g% and requiring regular blood transfusions. Seven patients were treated with 4000 U rHuEPO once weekly (Eritrogen, Boehringer Mannheim), 2 patients received 4000 U every 5 and 8 days, and the last one 4000 U every 10 days. The target hematocrit was 33% and Hb 10.0 g%. The CNS activity was recorded as visual (VEP), brainstem (BAER), and somatosensory (SEP)-evoked potentials. The mean Hb concentration increased from 6.9 +/- 1.2 g% to 10.3 +/- 1.6 g% (p < 0.001) over 8 weeks. There were no significant changes in urea, creatinine, and potassium levels, and urine output. rHuEPO induced a decrease in latency of P100 VEP, in the four main components of BAER, and in the P27-N35 intertime of SEP. Parallel to the improvement of red cell indices, patients experienced a dramatic improvement in well-being. The subcutaneous administration of a single vial of rHuEPO is safe, convenient, and inexpensive in CAPD. The role of rHuEPO treatment in improving the electrophysiological brain function in uremic and anemic patients remains to be studied and may not necessarily be based on improved cerebral oxygenation.

UI MeSH Term Description Entries
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010531 Peritoneal Dialysis, Continuous Ambulatory Portable peritoneal dialysis using the continuous (24 hours a day, 7 days a week) presence of peritoneal dialysis solution in the peritoneal cavity except for periods of drainage and instillation of fresh solution. CAPD,Continuous Ambulatory Peritoneal Dialysis
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004921 Erythropoietin Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
D005071 Evoked Potentials Electrical responses recorded from nerve, muscle, SENSORY RECEPTOR, or area of the CENTRAL NERVOUS SYSTEM following stimulation. They range from less than a microvolt to several microvolts. The evoked potential can be auditory (EVOKED POTENTIALS, AUDITORY), somatosensory (EVOKED POTENTIALS, SOMATOSENSORY), visual (EVOKED POTENTIALS, VISUAL), or motor (EVOKED POTENTIALS, MOTOR), or other modalities that have been reported. Event Related Potential,Event-Related Potentials,Evoked Potential,N100 Evoked Potential,P50 Evoked Potential,N1 Wave,N100 Evoked Potentials,N2 Wave,N200 Evoked Potentials,N3 Wave,N300 Evoked Potentials,N4 Wave,N400 Evoked Potentials,P2 Wave,P200 Evoked Potentials,P50 Evoked Potentials,P50 Wave,P600 Evoked Potentials,Potentials, Event-Related,Event Related Potentials,Event-Related Potential,Evoked Potential, N100,Evoked Potential, N200,Evoked Potential, N300,Evoked Potential, N400,Evoked Potential, P200,Evoked Potential, P50,Evoked Potential, P600,Evoked Potentials, N100,Evoked Potentials, N200,Evoked Potentials, N300,Evoked Potentials, N400,Evoked Potentials, P200,Evoked Potentials, P50,Evoked Potentials, P600,N1 Waves,N2 Waves,N200 Evoked Potential,N3 Waves,N300 Evoked Potential,N4 Waves,N400 Evoked Potential,P2 Waves,P200 Evoked Potential,P50 Waves,P600 Evoked Potential,Potential, Event Related,Potential, Event-Related,Potential, Evoked,Potentials, Event Related,Potentials, Evoked,Potentials, N400 Evoked,Related Potential, Event,Related Potentials, Event,Wave, N1,Wave, N2,Wave, N3,Wave, N4,Wave, P2,Wave, P50,Waves, N1,Waves, N2,Waves, N3,Waves, N4,Waves, P2,Waves, P50
D005260 Female Females
D006400 Hematocrit The volume of packed RED BLOOD CELLS in a blood specimen. The volume is measured by centrifugation in a tube with graduated markings, or with automated blood cell counters. It is an indicator of erythrocyte status in disease. For example, ANEMIA shows a low value; POLYCYTHEMIA, a high value. Erythrocyte Volume, Packed,Packed Red-Cell Volume,Erythrocyte Volumes, Packed,Hematocrits,Packed Erythrocyte Volume,Packed Erythrocyte Volumes,Packed Red Cell Volume,Packed Red-Cell Volumes,Red-Cell Volume, Packed,Red-Cell Volumes, Packed,Volume, Packed Erythrocyte,Volume, Packed Red-Cell,Volumes, Packed Erythrocyte,Volumes, Packed Red-Cell

Related Publications

B Di Paolo, and A Marini, and B Fiederling, and L Di Liberato, and P Santarelli, and S Bucciarelli, and S Stuard, and L Paolantonio, and A Albertazzi
Subcutaneous recombinant human erythropoietin in hemodialysis and continuous ambulatory peritoneal dialysis.
January 1993, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis,
B Di Paolo, and A Marini, and B Fiederling, and L Di Liberato, and P Santarelli, and S Bucciarelli, and S Stuard, and L Paolantonio, and A Albertazzi
Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
June 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation,
B Di Paolo, and A Marini, and B Fiederling, and L Di Liberato, and P Santarelli, and S Bucciarelli, and S Stuard, and L Paolantonio, and A Albertazzi
Subcutaneous recombinant human erythropoietin in children with renal anemia on continuous ambulatory peritoneal dialysis.
November 1993, Acta paediatrica (Oslo, Norway : 1992),
B Di Paolo, and A Marini, and B Fiederling, and L Di Liberato, and P Santarelli, and S Bucciarelli, and S Stuard, and L Paolantonio, and A Albertazzi
Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
February 1989, Lancet (London, England),
B Di Paolo, and A Marini, and B Fiederling, and L Di Liberato, and P Santarelli, and S Bucciarelli, and S Stuard, and L Paolantonio, and A Albertazzi
Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
November 1991, Clinical nephrology,
B Di Paolo, and A Marini, and B Fiederling, and L Di Liberato, and P Santarelli, and S Bucciarelli, and S Stuard, and L Paolantonio, and A Albertazzi
Subcutaneous administration of recombinant human erythropoietin to subjects on continuous ambulatory peritoneal dialysis: an erythrokinetic assessment.
June 1990, British journal of haematology,
B Di Paolo, and A Marini, and B Fiederling, and L Di Liberato, and P Santarelli, and S Bucciarelli, and S Stuard, and L Paolantonio, and A Albertazzi
Effects of recombinant human erythropoietin on fibrinolytic system in children on continuous ambulatory peritoneal dialysis.
January 1999, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis,
B Di Paolo, and A Marini, and B Fiederling, and L Di Liberato, and P Santarelli, and S Bucciarelli, and S Stuard, and L Paolantonio, and A Albertazzi
Pharmacokinetics and pharmacodynamics of subcutaneous and intraperitoneal administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
January 1990, Clinical nephrology,
B Di Paolo, and A Marini, and B Fiederling, and L Di Liberato, and P Santarelli, and S Bucciarelli, and S Stuard, and L Paolantonio, and A Albertazzi
Low-dose subcutaneous erythropoietin in continuous ambulatory peritoneal dialysis.
May 1991, American journal of hematology,
B Di Paolo, and A Marini, and B Fiederling, and L Di Liberato, and P Santarelli, and S Bucciarelli, and S Stuard, and L Paolantonio, and A Albertazzi
Intraperitoneal administration of recombinant human erythropoietin in children on continuous ambulatory peritoneal dialysis.
July 1992, European journal of pediatrics,
Copied contents to your clipboard!